Gene | Gene Full Name | DSI g | DPI g | pLI | Disease | Type | Score gda | EL gda | EI gda | N. PMIDs | N. SNPs gda | First Ref. | Last Ref. | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
prostate cancer associated transcript 1 | 0.575 | 0.615 |
|
disease | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 | |||||||||
|
zinc finger and BTB domain containing 38 | 0.663 | 0.615 | 1.00 |
|
phenotype | 0.100 | None | 1.000 | 18 | 12 | 2008 | 2019 | ||||||||
|
POU class 5 homeobox 1B | 0.670 | 0.346 | 2.9E-04 |
|
disease | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 | ||||||||
|
POU class 5 homeobox 1B | 0.670 | 0.346 | 2.9E-04 |
|
disease | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 | ||||||||
|
POU class 5 homeobox 1B | 0.670 | 0.346 | 2.9E-04 |
|
group | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 | ||||||||
|
POU class 5 homeobox 1B | 0.670 | 0.346 | 2.9E-04 |
|
disease | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 | ||||||||
|
POU class 5 homeobox 1B | 0.670 | 0.346 | 2.9E-04 |
|
disease | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 | ||||||||
|
POU class 5 homeobox 1B | 0.670 | 0.346 | 2.9E-04 |
|
disease | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 | ||||||||
|
POU class 5 homeobox 1B | 0.670 | 0.346 | 2.9E-04 |
|
disease | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 | ||||||||
|
POU class 5 homeobox 1B | 0.670 | 0.346 | 2.9E-04 |
|
phenotype | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 | ||||||||
|
POU class 5 homeobox 1B | 0.670 | 0.346 | 2.9E-04 |
|
disease | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 | ||||||||
|
cancer susceptibility 8 | 0.670 | 0.462 |
|
disease | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 | |||||||||
|
cancer susceptibility 8 | 0.670 | 0.462 |
|
disease | 0.140 | None | 1.000 | 18 | 5 | 2007 | 2019 | |||||||||
|
cancer susceptibility 8 | 0.670 | 0.462 |
|
group | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 | |||||||||
|
cancer susceptibility 8 | 0.670 | 0.462 |
|
disease | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 | |||||||||
|
cancer susceptibility 8 | 0.670 | 0.462 |
|
disease | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 | |||||||||
|
cancer susceptibility 8 | 0.670 | 0.462 |
|
disease | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 | |||||||||
|
cancer susceptibility 8 | 0.670 | 0.462 |
|
disease | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 | |||||||||
|
cancer susceptibility 8 | 0.670 | 0.462 |
|
phenotype | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 | |||||||||
|
cancer susceptibility 8 | 0.670 | 0.462 |
|
disease | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 | |||||||||
|
cadherin EGF LAG seven-pass G-type receptor 2 | 0.656 | 0.577 | 1.00 |
|
phenotype | 0.100 | None | 1.000 | 17 | 7 | 2008 | 2019 | ||||||||
|
fibroblast growth factor receptor 2 | 0.380 | 0.808 | 1.00 |
|
disease | 0.500 | None | 0.943 | 17 | 14 | 1996 | 2020 | ||||||||
|
3-hydroxy-3-methylglutaryl-CoA reductase | 0.529 | 0.692 | 1.00 |
|
phenotype | 0.100 | None | 1.000 | 17 | 8 | 2008 | 2019 | ||||||||
|
low density lipoprotein receptor | 0.449 | 0.885 | 9.8E-24 |
|
phenotype | 0.100 | None | 1.000 | 17 | 9 | 2008 | 2019 | ||||||||
|
SMAD family member 7 | 0.470 | 0.769 | 0.55 |
|
disease | 0.160 | None | 1.000 | 17 | 7 | 2007 | 2019 |